Compare Moderna, Inc. (MRNA) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Workiva Inc — how do they compare? Moderna, Inc. trades at $63.57 (market cap $24.18B), while Workiva Inc trades at $67.9 (market cap $3.76B). The key difference: Moderna, Inc. is far larger — about 6.4× Workiva Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | WK | |
|---|---|---|
Market Cap | $24.18B | $3.76B |
Sector | Health | Technology |
52-Week High | $81.80 | $93.31 |
52-Week Low | $22.36 | $44.31 |
Enterprise Value | $20.33B | $3.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
WK trades at $67.73, up 0.61% today, near its consensus price target of $69. The stock shows bullish technical signals with strong moving average support and recent earnings beats. Revenue grew to $966 million in 2026 with net income turning positive at $47 million, reflecting improved profitability. Positive sentiment is driven by AI product launches and consistent earnings outperformance.
Outlook remains positive given earnings momentum and AI innovation, but high valuation multiples pose risks. Investors face elevated P/E and EV/EBITDA ratios, requiring sustained growth to justify premiums. Competitive pressures and execution on AI initiatives are key to maintaining upward trajectory amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
